Cellectis S.A.
CLLSHealthcare|Biotechnology|FR
$1.07
+0.04 (+3.88%)
Tangible Book / Share
$0.40
Cash / Share
$1.66
Financials
Financial Snapshot
Market Cap
$107.8M
Enterprise Value
$130.0M
Revenue (TTM)
$56.6M
Net Income (TTM)
-$65.3M
Cash & Investments
$166.8M
Net Cash
$82.3M
Free Cash Flow (TTM)
-$44.1M
Operating CF (TTM)
-$41.9M
Debt/Equity
2.06
Cash Runway & Burn Rate
Cash on Hand
$166.8M
Quarterly Burn
$10.5M
Monthly Burn
$3.5M
Est. Runway
~15.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $290.5M | $297.0M | $451.9M | $360.9M | $268.2M | $186.1M | $97.7M | $203.8M | $260.3M | $208.7M | $166.8M | |
| Operating Cash Flow | -$31.1M | -$52.3M | -$68.1M | -$69.1M | -$80.3M | -$104.6M | -$87.4M | -$24.7M | $22.1M | -$40.1M | -$41.9M | |
| Free Cash Flow | -$44.4M | -$55.0M | -$73.0M | -$82.1M | -$124.7M | -$123.1M | -$89.9M | -$25.8M | $19.5M | -$42.5M | -$44.1M | |
| Capital Expenditure | -$13.3M | -$2.7M | -$4.9M | -$13.0M | -$44.4M | -$18.6M | -$2.4M | -$1.1M | -$2.6M | -$2.4M | -$2.2M | |
| Financing Cash Flow | $460.6K | $41.3M | $236.5M | -$3.9M | $27.3M | $47.5M | $1.1M | $82.9M | $89.8M | -$16.2M | -$16.4M |
R&D Spending
R&D (TTM)
$92.5M
R&D Intensity
163.4%
R&D Growth vs Prior
-1.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.6M | $25.2M | $12.7M | $15.2M | $51.1M | $30.3M | $19.2M | $755.0K | $41.5M | $72.9M | $56.6M | |
| R&D Expense | $74.6M | $79.2M | $76.6M | $92.0M | $77.0M | $117.8M | $97.5M | $87.6M | $90.5M | $93.5M | $92.5M | |
| R&D % of Revenue | 175.1% | 314.5% | 601.4% | 605.9% | 150.9% | 388.3% | 508.6% | 11608.7% | 218.1% | 128.2% | 163.4% | |
| SG&A | $41.3M | $44.8M | $47.2M | $43.0M | $22.5M | $22.9M | $8.9M | $8.1M | $8.4M | $8.6M | $12.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.6M | $25.2M | $12.7M | $15.2M | $51.1M | $30.3M | $19.2M | $755.0K | $41.5M | $72.9M | $56.6M | |
| Cost of Revenue | $1.7M | $2.6M | $2.7M | $11.4M | $2.0M | $1.8M | $8.5M | $7.4M | $9.2M | $9.8M | $14.3M | |
| Gross Profit | $40.9M | $22.6M | $10.0M | $3.8M | $49.1M | $28.5M | $10.7M | -$6.7M | $32.3M | $63.2M | $42.3M | |
| R&D | $74.6M | $79.2M | $76.6M | $92.0M | $77.0M | $117.8M | $97.5M | $87.6M | $90.5M | $93.5M | $92.5M | |
| SG&A | $41.3M | $44.8M | $47.2M | $43.0M | $22.5M | $22.9M | $8.9M | $8.1M | $8.4M | $8.6M | $12.3M | |
| Operating Income | -$64.0M | -$92.7M | -$105.1M | -$123.6M | -$42.3M | -$103.5M | -$89.7M | -$97.3M | -$59.6M | -$33.1M | -$61.9M | |
| Interest Expense | $6.3K | $560.0K | $723.0K | $3.0M | $3.7M | $4.2M | $3.8M | $5.3M | $7.5M | $8.1M | $8.4M | |
| Pretax Income | -$63.9M | -$103.7M | -$88.3M | -$115.2M | -$53.6M | -$96.8M | -$98.6M | -$116.5M | -$36.8M | -$68.0M | -$69.2M | |
| Net Income | -$63.9M | -$99.4M | -$78.7M | -$102.1M | -$81.1M | -$114.2M | -$106.1M | -$101.1M | -$36.8M | -$67.6M | -$65.3M | |
| EPS (Diluted) | -1.78 | -2.78 | -1.93 | -2.14 | -1.71 | -2.69 | -2.33 | -1.77 | -0.41 | -0.68 | -0.66 | |
| EBITDA | -$65.0M | -$108.1M | -$93.8M | -$105.7M | -$43.3M | -$78.4M | -$76.4M | -$92.6M | -$9.5M | -$39.8M | -$55.5M | |
| Shares Out. (M) | 35.81 | 35.69 | 40.77 | 42.44 | 42.50 | 42.45 | 45.55 | 57.01 | 90.57 | 100.28 | 100.65 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $290.5M | $297.0M | $451.9M | $360.9M | $241.1M | $185.6M | $89.8M | $136.7M | $143.3M | $63.6M | $35.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $27.1M | $499.0K | $7.9M | $67.1M | $117.1M | $145.1M | $131.3M | |
| Total Current Assets | $311.8M | $323.2M | $487.6M | $391.5M | $315.4M | $225.4M | $143.8M | $233.0M | $287.1M | $236.2M | $184.4M | |
| Total Assets | $330.7M | $332.9M | $500.8M | $467.5M | $469.5M | $382.1M | $261.2M | $334.3M | $383.5M | $324.7M | $267.4M | |
| Total Current Liabilities | $56.0M | $43.5M | $46.9M | $62.6M | $52.0M | $49.3M | $63.0M | $155.1M | $166.3M | $145.8M | $135.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $24.2M | $18.8M | $13.6M | $28.4M | $44.0M | $74.0M | $52.7M | |
| Total Liabilities | $56.6M | $47.0M | $50.6M | $112.0M | $160.6M | $145.6M | $135.3M | $249.6M | $252.5M | $248.8M | $226.3M | |
| Stockholders' Equity | $272.2M | $266.8M | $409.3M | $315.1M | $283.8M | $221.3M | $118.0M | $84.7M | $131.0M | $75.9M | $41.1M | |
| Retained Earnings | -$229.8M | -$351.3M | -$405.3M | -$508.5M | -$587.0M | -$698.3M | -$439.5M | -$405.8M | -$329.6M | -$334.1M | -$303.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31.1M | -$52.3M | -$68.1M | -$69.1M | -$80.3M | -$104.6M | -$87.4M | -$24.7M | $22.1M | -$40.1M | -$41.9M | |
| Capital Expenditure | -$13.3M | -$2.7M | -$4.9M | -$13.0M | -$44.4M | -$18.6M | -$2.4M | -$1.1M | -$2.6M | -$2.4M | -$2.2M | |
| Free Cash Flow | -$44.4M | -$55.0M | -$73.0M | -$82.1M | -$124.7M | -$123.1M | -$89.9M | -$25.8M | $19.5M | -$42.5M | -$44.1M | |
| Investing Cash Flow | -$50.5M | $1.8M | $35.6M | -$35.9M | -$54.3M | $7.3M | -$2.8M | -$15.5M | -$102.6M | -$29.6M | $31.7M | |
| Financing Cash Flow | $460.6K | $41.3M | $236.5M | -$3.9M | $27.3M | $47.5M | $1.1M | $82.9M | $89.8M | -$16.2M | -$16.4M | |
| Issuance of Stock | $713.0K | $41.3M | $228.8M | $0.00 | $9.2M | $44.6M | $0.00 | $67.9M | $82.7M | $44.1K | $248.2K | |
| Repurchase of Stock | -$137.0K | $0.00 | $0.00 | -$469.0K | $0.00 | $0.00 | -$569.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$91.0K | -$41.0K | -$127.0K | -$3.4M | $19.4M | -$10.6M | -$6.6M | $24.6M | $18.2M | -$5.4M | -$10.2M | |
| Stock Based Comp. | $55.7M | $50.4M | $37.2M | $26.9M | $10.0M | $11.5M | $6.0M | $5.2M | $0.00 | $0.00 | $2.3M | |
| Net Change in Cash | -$76.5M | $1.8M | $195.1M | -$111.0M | -$99.4M | -$55.5M | -$92.4M | $43.5M | $6.5M | -$79.7M | -$26.1M |
Dilution Tracker
Shares outstanding grew 135.9% over 5 years — significant dilution
Shares Outstanding
101M
5-Year Share Growth
+135.9%
Stock Issuance (TTM)
$248.2K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 35.81 | 35.69 | 40.77 | 42.44 | 42.50 | 42.45 | 45.55 | 57.01 | 90.57 | 100.28 | 100.65 | |
| Change vs Prior % | — | -0.3% | 14.2% | 4.1% | 0.1% | -0.1% | 7.3% | 25.2% | 58.9% | 10.7% | 0.4% | |
| Stock Issuance | $713.0K | $41.3M | $228.8M | $0.00 | $9.2M | $44.6M | $0.00 | $67.9M | $82.7M | $44.1K | $248.2K | |
| Stock Repurchase | -$137.0K | $0.00 | $0.00 | -$469.0K | $0.00 | $0.00 | -$569.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $55.7M | $50.4M | $37.2M | $26.9M | $10.0M | $11.5M | $6.0M | $5.2M | $0.00 | $0.00 | $2.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 96.0% | 89.6% | 78.5% | 25.0% | 96.2% | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% | 74.7% | |
| Operating Margin % | -150.2% | -367.8% | -825.5% | -813.4% | -82.9% | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% | -109.3% | |
| Net Margin % | -150.1% | -394.5% | -618.1% | -672.1% | -158.8% | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% | -115.5% | |
| EBITDA Margin % | -152.7% | -429.1% | -736.7% | -696.1% | -84.9% | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% | -98.1% | |
| FCF Margin % | -104.3% | -218.3% | -573.6% | -540.5% | -244.2% | -405.7% | -468.9% | -3419.7% | 47.0% | -58.3% | -77.9% | |
| ROE % | -23.5% | -37.2% | -19.2% | -32.4% | -28.6% | -51.6% | -90.0% | -119.3% | -28.1% | -89.1% | -94.1% | |
| ROA % | -19.3% | -29.9% | -15.7% | -21.8% | -17.3% | -29.9% | -40.6% | -30.2% | -9.6% | -20.8% | -24.4% | |
| ROIC % | -22.6% | -27.9% | -23.1% | -30.4% | -10.0% | -30.1% | -42.5% | -50.5% | -25.8% | -16.7% | -41.0% | |
| R&D / Revenue % | 175.1% | 314.5% | 601.4% | 605.9% | 150.9% | 388.3% | 508.6% | 11608.7% | 218.1% | 128.2% | 163.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -22.6% | -40.9% | -49.5% | 19.3% | 236.1% | -40.6% | -36.8% | -96.1% | 5397.5% | 75.8% | |
| Gross Profit | -21.9% | -44.8% | -55.7% | -62.0% | 1192.9% | -42.0% | -62.5% | -162.4% | 585.1% | 95.4% | |
| Operating Income | -109.5% | -44.9% | -13.4% | -17.6% | 65.8% | -144.6% | 13.4% | -8.5% | 38.8% | 44.5% | |
| Net Income | -184.6% | -55.5% | 20.8% | -29.7% | 20.6% | -40.9% | 7.1% | 4.8% | 63.6% | -83.9% | |
| EPS (Diluted) | -173.8% | -56.2% | 30.6% | -10.9% | 20.1% | -57.3% | 13.4% | 24.0% | 76.8% | -65.9% | |
| Operating Cash Flow | -978.7% | -68.3% | -30.2% | -1.5% | -16.1% | -30.3% | 16.4% | 71.7% | 189.3% | -281.6% | |
| Free Cash Flow | -6113.1% | -23.8% | -32.8% | -12.4% | -51.9% | 1.3% | 27.0% | 71.3% | 175.6% | -317.7% | |
| R&D Expense | 30.1% | 6.3% | -3.4% | 20.2% | -16.3% | 52.9% | -17.3% | -10.1% | 3.3% | 3.3% | |
| SG&A Expense | 38.5% | 8.5% | 5.6% | -9.0% | -47.7% | 1.6% | -61.1% | -8.7% | 3.7% | 2.1% | |
| Total Assets | -11.3% | 0.7% | 50.5% | -6.7% | 0.4% | -18.6% | -31.6% | 28.0% | 14.7% | -15.3% | |
| Book Value / Share | -8.0% | 3.2% | 37.9% | -24.2% | -13.2% | -23.3% | -50.4% | -46.3% | -2.6% | -47.7% | |
| Debt | -19.2% | -98.1% | 3873.5% | 3423.8% | 124.1% | -5.4% | -24.9% | 12.3% | 7.5% | 31.1% | |
| Diluted Shares | 3.7% | -0.3% | 14.2% | 4.1% | 0.1% | -0.1% | 7.3% | 25.2% | 58.9% | 10.7% |
Valuation
P/E (TTM)At Loss
P/S1.43
10Y Low / Med / High3.93 / 22.53 / 232.58
P/B2.75
10Y Low / Med / High0.81 / 2.20 / 6.39
EV/EBITDAAt Loss
EV/Revenue2.30
10Y Low / Med / High2.68 / 17.94 / 164.17
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.40
Cash / Share
$1.66
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -9.36 | -10.49 | -8.63 | -8.00 | -15.82 | -3.02 | -0.90 | -1.74 | -4.39 | -7.12 | -1.71 | |
| P/S Ratio | 14.05 | 41.30 | 53.32 | 47.83 | 22.53 | 11.36 | 4.99 | 232.58 | 3.93 | 6.65 | 1.43 | |
| P/B Ratio | 2.20 | 3.90 | 1.66 | 2.31 | 4.05 | 1.56 | 0.81 | 2.07 | 1.24 | 6.39 | 2.75 | |
| EV/EBITDA | -4.76 | -6.88 | -2.43 | -3.91 | -23.43 | -3.31 | -1.07 | -1.34 | -11.76 | -13.59 | -2.98 | |
| EV/Revenue | 7.27 | 29.52 | 17.94 | 27.21 | 19.89 | 8.56 | 4.26 | 164.17 | 2.68 | 7.43 | 2.30 |
Analyst Estimates & Quality
Altman Z-Score
-1.79
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $53.6M | $85.3M | $73.5M |
| Net Income | -$80.6M | -$66.9M | -$134.5M |
| EPS | $-0.80 | $-0.67 | $-1.34 |
| # Analysts (EPS) | 5 | 4 | 2 |
Revenue Segments
By Product
| Segment | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| High Oleic Soyabean Oil | $1.7M | $22.9M | $27.0M | — |
| ALLO715 | $5.0M | $28.5M | — | — |
| High Oleic Soyabean Meal | $5.6M | — | — | — |
| Therapeutics | — | — | — | $25.7M |
By Geography
| Segment | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|
| FRANCE | $7.9M | $51.1M | $30.3M | $19.2M | $755.0K | $72.9M |
| UNITED STATES | $7.3M | $22.9M | $26.9M | — | — | — |